Screening for human papillomavirus–associated cervical disease in HIV-infected women

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

HIV-infected women have higher rates of persistence of human papillomavirus (HPV) infection, of abnormal cervical cytology results, and of cervical cancer than uninfected women. It is currently recommended that HIVinfected, sexually active women have a Papanicolaou (Pap) test performed at the time of initial diagnosis of HIV infection, followed by annual Pap testing if the previous test result is normal. Women whose test results show abnormalities greater than atypical squamous cells of undetermined significance (ASCUS) should be referred for colposcopy. Those with ASCUS should undergo immediate colposcopy or repeat cervical cytology in 6 months to 12 months, and those whose repeat cervical cytology results show ASCUS or greater abnormalities should undergo colposcopy. Recent findings indicate that screening intervals can be lengthened for HIVinfected women whose Pap test results are persistently normal and who are engaged in routine care, and that HPV DNA testing may have a role in screening. This article summarizes a presentation by Marla J. Keller, MD, at the IAS–USA continuing education program, Improving the Management of HIV Disease, held in Atlanta, Georgia, in March 2015.

Original languageEnglish (US)
Pages (from-to)142-145
Number of pages4
JournalTopics in antiviral medicine
Volume23
Issue number4
StatePublished - Oct 1 2015

Fingerprint

Colposcopy
HIV
Cell Biology
Papanicolaou Test
Papillomavirus Infections
Continuing Education
Disease Management
Uterine Cervical Neoplasms
HIV Infections
DNA
Atypical Squamous Cells of the Cervix

Keywords

  • Cervical cancer screening
  • Cervical cytology
  • HIV
  • HPV
  • Human papillomavirus
  • Oncogenic HPV DNA testing

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology
  • Virology

Cite this

Screening for human papillomavirus–associated cervical disease in HIV-infected women. / Keller, Marla J.

In: Topics in antiviral medicine, Vol. 23, No. 4, 01.10.2015, p. 142-145.

Research output: Contribution to journalArticle

@article{06dafed9742d4ba9b99da1824dcd4088,
title = "Screening for human papillomavirus–associated cervical disease in HIV-infected women",
abstract = "HIV-infected women have higher rates of persistence of human papillomavirus (HPV) infection, of abnormal cervical cytology results, and of cervical cancer than uninfected women. It is currently recommended that HIVinfected, sexually active women have a Papanicolaou (Pap) test performed at the time of initial diagnosis of HIV infection, followed by annual Pap testing if the previous test result is normal. Women whose test results show abnormalities greater than atypical squamous cells of undetermined significance (ASCUS) should be referred for colposcopy. Those with ASCUS should undergo immediate colposcopy or repeat cervical cytology in 6 months to 12 months, and those whose repeat cervical cytology results show ASCUS or greater abnormalities should undergo colposcopy. Recent findings indicate that screening intervals can be lengthened for HIVinfected women whose Pap test results are persistently normal and who are engaged in routine care, and that HPV DNA testing may have a role in screening. This article summarizes a presentation by Marla J. Keller, MD, at the IAS–USA continuing education program, Improving the Management of HIV Disease, held in Atlanta, Georgia, in March 2015.",
keywords = "Cervical cancer screening, Cervical cytology, HIV, HPV, Human papillomavirus, Oncogenic HPV DNA testing",
author = "Keller, {Marla J.}",
year = "2015",
month = "10",
day = "1",
language = "English (US)",
volume = "23",
pages = "142--145",
journal = "Topics in antiviral medicine",
issn = "2161-5853",
publisher = "International Antiviral Society",
number = "4",

}

TY - JOUR

T1 - Screening for human papillomavirus–associated cervical disease in HIV-infected women

AU - Keller, Marla J.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - HIV-infected women have higher rates of persistence of human papillomavirus (HPV) infection, of abnormal cervical cytology results, and of cervical cancer than uninfected women. It is currently recommended that HIVinfected, sexually active women have a Papanicolaou (Pap) test performed at the time of initial diagnosis of HIV infection, followed by annual Pap testing if the previous test result is normal. Women whose test results show abnormalities greater than atypical squamous cells of undetermined significance (ASCUS) should be referred for colposcopy. Those with ASCUS should undergo immediate colposcopy or repeat cervical cytology in 6 months to 12 months, and those whose repeat cervical cytology results show ASCUS or greater abnormalities should undergo colposcopy. Recent findings indicate that screening intervals can be lengthened for HIVinfected women whose Pap test results are persistently normal and who are engaged in routine care, and that HPV DNA testing may have a role in screening. This article summarizes a presentation by Marla J. Keller, MD, at the IAS–USA continuing education program, Improving the Management of HIV Disease, held in Atlanta, Georgia, in March 2015.

AB - HIV-infected women have higher rates of persistence of human papillomavirus (HPV) infection, of abnormal cervical cytology results, and of cervical cancer than uninfected women. It is currently recommended that HIVinfected, sexually active women have a Papanicolaou (Pap) test performed at the time of initial diagnosis of HIV infection, followed by annual Pap testing if the previous test result is normal. Women whose test results show abnormalities greater than atypical squamous cells of undetermined significance (ASCUS) should be referred for colposcopy. Those with ASCUS should undergo immediate colposcopy or repeat cervical cytology in 6 months to 12 months, and those whose repeat cervical cytology results show ASCUS or greater abnormalities should undergo colposcopy. Recent findings indicate that screening intervals can be lengthened for HIVinfected women whose Pap test results are persistently normal and who are engaged in routine care, and that HPV DNA testing may have a role in screening. This article summarizes a presentation by Marla J. Keller, MD, at the IAS–USA continuing education program, Improving the Management of HIV Disease, held in Atlanta, Georgia, in March 2015.

KW - Cervical cancer screening

KW - Cervical cytology

KW - HIV

KW - HPV

KW - Human papillomavirus

KW - Oncogenic HPV DNA testing

UR - http://www.scopus.com/inward/record.url?scp=84949483803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949483803&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 142

EP - 145

JO - Topics in antiviral medicine

JF - Topics in antiviral medicine

SN - 2161-5853

IS - 4

ER -